诺和诺德:GLP-1/GIP/GCG启动减重二期临床

医药笔记
Feb 10

▎Armstrong2026年2月9日,诺和诺德在Clinicaltrials.gov网站上注册了UBT251用于治疗肥胖的全球二期临床试验。该二期临床计划入组333例肥胖或超重受试者,预计2027年1月完成。UBT251为联邦制药自主研发的GLP-1/GIP/GCG受体激动剂。根据2024年披露的一期临床数据,半衰期为136-170小时,支持每周一次给药,1.0-4.5mg剂量范围内,体重下降...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10